A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Key Inclusion Criteria: * Signed informed consent obtained prior to participation in the study * Male and female adult participants \>= 18 years of age * CSU duration for \>= 6 months prior to screening (defined as the onset of CSU determined by the Investigator based on all available supporting documentation). * Diagnosis of CSU inadequately controlled by second generation H1-AH at the time of baseline (Day 1) * Documentation of hives within three months before baseline (either at screening and/or at baseline (Day 1); or documented in the participants' medical history). * Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the protocol * Participants had no more than 2 missing UPDD entries (either morning or evening) in the 7 days prior to baseline (Day 1). Key Exclusion Criteria: * Participants unable to tolerate 24-hour ambulatory blood pressure measurement using automatic ABPM device * Ongoing or past history of hypertension and/or SBP \>= 140 or =\< 90 OR DBP \>= 90 or =\< 60 mmHg at screening * Participants working night shifts * Participants taking/requiring medications prohibited by the protocol (including those known to interfere with blood pressure assessments in the study) * Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the Investigator's opinio…